Syfovre, also known as pegcetacoplan, is a medicine used to treat geographic atrophy, which is the advanced form of dry age-related macular degeneration. Geographic atrophy can cause ...

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it down for ...

Apellis Pharmaceuticals (NASDAQ:APLS) said early Thursday that a total of ten cases of retinal vasculitis have been confirmed with two more suspected among recipients of its eye medication Syfovre.

Citi added that Syfovre was “still well on-pace” to reach around $700M in fiscal 2024, “reflecting a very strong launch.” ...

Apellis' share price came under pressure today after it revealed new details about a rare but serious side effect with its recently-approved Syfovre therapy for eye disease geographic atrophy (GA).

Both Izervay and Syfovre are eye injections used to treat geographic atrophy caused by AMD. They work similarly to one another to manage this condition. Because of this, they can cause some ...

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...

MoA International Fund earns a High Process Pillar rating. The main driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's average 10-year ...

“We have continued to execute well and progress our programs over the past six months. SYFOVRE delivered strong growth and is reaching more people living with geographic atrophy, EMPAVELI ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)’s two primary revenue generating treatments EMPAVELI and SYFOVRE are primarily targeted towards people with eye diseases. The firm is also trying to ...

Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in ...